Key Takeaways & Executive Findings
- •• The overall incidence of adverse drug reactions (ADRs) after COVID-19 vaccination is 62.3%, with local reactions being the most common (78.5%). • Serious ADRs are extremely rare (0.08%), confirming the overall safety of COVID-19 vaccines. • Younger adults and females are more likely to experience ADRs, and mRNA vaccines are associated with a higher incidence of systemic reactions. • The findings provide robust evidence to support the continued use of COVID-19 vaccines in public health campaigns.
Abstract
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and characteristics of ADRs associated with COVID-19 vaccines. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to March 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates. Results: A total of 45 studies involving 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4). Local reactions were most common (78.5%), followed by systemic reactions (45.2%). The most frequent local reaction was injection site pain (70.2%), and the most frequent systemic reactions were fatigue (34.5%), headache (28.7%), and myalgia (22.3%). Serious ADRs were rare (0.08%). The incidence of ADRs was higher in younger adults and females. mRNA vaccines had a higher incidence of systemic reactions compared to viral vector vaccines. Conclusion: COVID-19 vaccines are generally safe, with mostly mild and transient ADRs. The findings support the continued use of COVID-19 vaccines to combat the pandemic.
1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. The rapid development of effective vaccines has been a cornerstone in controlling the pandemic. However, the widespread administration of COVID-19 vaccines has been accompanied by reports of adverse drug reactions (ADRs), ranging from mild local reactions to rare serious events. Understanding the incidence and spectrum of these ADRs is crucial for healthcare providers, policymakers, and the public to make informed decisions about vaccination.
Several studies have reported on the safety of COVID-19 vaccines, but there is considerable variability in the incidence and types of ADRs across different populations and vaccine platforms. A comprehensive synthesis of the available evidence is needed to provide a clear picture of the safety profile of these vaccines. This systematic review and meta-analysis aims to evaluate the incidence and characteristics of ADRs associated with COVID-19 vaccines, with a focus on identifying factors that may influence their occurrence.
Loading authentic research manuscript (Pages 1–5)...
Zhang Wei, Li Na, Wang Fang, Chen Yu, Liu Yang (2026). Adverse Drug Reactions Related to COVID-19 Vaccination: A Systematic Review and Meta-Analysis. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the overall incidence of adverse drug reactions after COVID-19 vaccination?
The overall incidence of any adverse drug reaction (ADR) after COVID-19 vaccination is 62.3%, with local reactions being the most common (78.5%), followed by systemic reactions (45.2%).
Are serious adverse drug reactions common after COVID-19 vaccination?
No, serious ADRs are extremely rare, with an incidence of only 0.08%. The majority of ADRs are mild and transient, such as injection site pain, fatigue, and headache.
Which populations are more likely to experience adverse drug reactions after COVID-19 vaccination?
Younger adults and females are more likely to experience ADRs. Additionally, mRNA vaccines are associated with a higher incidence of systemic reactions compared to viral vector vaccines.
What are the most common local and systemic adverse drug reactions?
The most common local reaction is injection site pain (70.2%), while the most common systemic reactions are fatigue (34.5%), headache (28.7%), and myalgia (22.3%).
Should the findings of this study affect COVID-19 vaccination recommendations?
No, the findings support the continued use of COVID-19 vaccines, as the benefits of vaccination in preventing severe disease and death far outweigh the risks of mild and transient ADRs.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.